RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Robert A. Nichols to Neuroprotective Agents

This is a "connection" page, showing publications Robert A. Nichols has written about Neuroprotective Agents.
Connection Strength

1.267
  1. Forest KH, Nichols RA. Assessing Neuroprotective Agents for A?-Induced Neurotoxicity. Trends Mol Med. 2019 08; 25(8):685-695.
    View in: PubMed
    Score: 0.560
  2. Forest KH, Alfulaij N, Arora K, Taketa R, Sherrin T, Todorovic C, Lawrence JLM, Yoshikawa GT, Ng HL, Hruby VJ, Nichols RA. Protection against ?-amyloid neurotoxicity by a non-toxic endogenous N-terminal ?-amyloid fragment and its active hexapeptide core sequence. J Neurochem. 2018 01; 144(2):201-217.
    View in: PubMed
    Score: 0.504
  3. Tan X, Liang Z, Li Y, Zhi Y, Yi L, Bai S, Forest KH, Nichols RA, Dong Y, Li QX. Isoorientin, a GSK-3? inhibitor, rescues synaptic dysfunction, spatial memory deficits and attenuates pathological progression in APP/PS1 model mice. Behav Brain Res. 2021 02 01; 398:112968.
    View in: PubMed
    Score: 0.153
  4. Roberts CF, Cao Y, Im W, Nichols RA, Lukas RJ, George AA. Neuroprotective amyloid ? N-terminal peptides differentially alter human a7- and a7?2-nicotinic acetylcholine (nACh) receptor single-channel properties. Br J Pharmacol. 2024 Sep; 181(17):3172-3191.
    View in: PubMed
    Score: 0.049
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support